RAYLAPharmaceuticals
Raymed Labs Ltd — Cash Flow Statement
₹3.83
+0.00%
Raymed Labs Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -0.59 Cr | -0.06 Cr | -0.16 Cr | -2.21 Cr | — |
| Issuance Of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 | — |
| End Cash Position | 1000.00 | 5000.00 | 5490.00 | 26030.00 | — |
| Other Cash Adjustment Outside Changein Cash | -4000.00 | — | — | — | — |
| Beginning Cash Position | 5000.00 | 5000.00 | 7030.00 | 17680.00 | — |
| Changes In Cash | 0.00 | 0.00 | -1540.00 | 8350.00 | — |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Issuance Payments Of Debt | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Short Term Debt Issuance | 0.00 | 0.00 | — | — | — |
| Net Long Term Debt Issuance | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Investing Cash Flow | 0.59 Cr | 0.06 Cr | 0.16 Cr | 2.21 Cr | — |
| Interest Received Cfi | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Dividends Received Cfi | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Investment Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Investment Properties Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Purchase Of Investment Properties | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | 0.65 Cr | 0.00 | 0.00 | 0.00 | — |
| Sale Of PPE | 0.65 Cr | 0.00 | 0.00 | 0.00 | — |
| Purchase Of PPE | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Operating Cash Flow | -0.59 Cr | -0.06 Cr | -0.16 Cr | -2.21 Cr | — |
| Taxes Refund Paid | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Interest Paid Cfo | -0.11 Cr | 0.00 | 0.00 | 0.00 | — |
| Change In Working Capital | 0.09 Cr | -22000.00 | -0.06 Cr | -2.13 Cr | — |
| Change In Other Current Liabilities | 0.12 Cr | 0.00 | -0.06 Cr | -2.13 Cr | — |
| Change In Other Current Assets | -0.03 Cr | 0.00 | 0.00 | 0.00 | — |
| Change In Inventory | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Change In Receivables | 45000.00 | 0.00 | 0.00 | 9500.00 | — |
| Other Non Cash Items | 0.11 Cr | 0.04 Cr | 0.06 Cr | 0.04 Cr | — |
| Depreciation And Amortization | 44000.00 | 48000.00 | 54620.00 | 51720.00 | — |
| Depreciation | 44000.00 | 48000.00 | 51720.00 | 51720.00 | — |
| Gain Loss On Sale Of PPE | -0.51 Cr | 0.00 | — | — | — |
| Net Income From Continuing Operations | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Effect Of Exchange Rate Changes | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Change In Payable | — | -22000.00 | 20000.00 | -28000.00 | 6000.00 |
| Provisionand Write Offof Assets | — | 0.04 Cr | -0.06 Cr | 0.03 Cr | 0.03 Cr |
| Amortization Cash Flow | — | 0.00 | 2900.00 | — | — |
| Sale Of Business | — | — | 0.00 | 0.00 | 0.00 |
| Purchase Of Business | — | — | 0.00 | 0.00 | 0.00 |
| Repurchase Of Capital Stock | — | — | 0.00 | 0.00 | 0.00 |
| Repayment Of Debt | — | — | 0.00 | 0.00 | 0.00 |
| Issuance Of Debt | — | — | 0.00 | 0.00 | 0.00 |
| Interest Paid Cff | — | — | 0.00 | 0.00 | 0.00 |
| Common Stock Payments | — | — | 0.00 | 0.00 | 0.00 |
| Long Term Debt Payments | — | — | 0.00 | 0.00 | 0.00 |
| Long Term Debt Issuance | — | — | 0.00 | 0.00 | 0.00 |
| Sale Of Investment | — | — | 0.00 | 0.00 | 0.00 |
| Purchase Of Investment | — | — | 0.00 | 0.00 | 0.00 |
| Net Business Purchase And Sale | — | — | 0.00 | 0.00 | 0.00 |
| Net Intangibles Purchase And Sale | — | — | 0.00 | 0.00 | 0.00 |
| Sale Of Intangibles | — | — | 0.00 | 0.00 | 0.00 |
| Purchase Of Intangibles | — | — | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Reported | — | — | 0.00 | 0.00 | 0.00 |
| Interest Received Cfo | — | — | 0.00 | 0.00 | 0.00 |
| Dividend Received Cfo | — | — | 0.00 | 0.00 | 0.00 |
| Stock Based Compensation | — | — | 0.00 | 0.00 | 0.00 |
| Net Foreign Currency Exchange Gain Loss | — | — | 0.00 | 0.00 | 0.00 |
| Sale Of Investment Properties | — | — | — | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Raymed Labs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.